This phase III trial investigates the best dose of vinblastine in combination with
selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib
alone in treating children and young adults with low-grade glioma (a common type of brain
cancer) that has come back after prior treatment (recurrent) or does not respond to therapy
(progressive). Selumetinib is a drug that works by blocking a protein that lets tumor cells
grow without stopping. Vinblastine blocks cell growth by stopping cell division and may kill
cancer cells. Giving selumetinib in combination with vinblastine may work better than
selumetinib alone in treating recurrent or progressive low-grade glioma.

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

Fargo

Sanford Broadway Medical Center

Biospecimen Collection

Magnetic Resonance Imaging

Quality-of-Life Assessment

Questionnaire Administration

Selumetinib Sulfate

Vinblastine Sulfate

A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations

This phase II trial studies how well the combination of dabrafenib and trametinib works after
radiation therapy in children and young adults with high grade glioma who have a genetic
change called BRAF V600 mutation. Radiation therapy uses high energy rays to kill tumor cells
and reduce the size of tumors. Dabrafenib and trametinib may stop the growth of tumor cells
by blocking BRAF and MEK, respectively, which are enzymes that tumor cells need for their
growth. Giving dabrafenib with trametinib after radiation therapy may work better than
treatments used in the past in patients with newly-diagnosed BRAF V600-mutant high-grade
glioma.

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

Dabrafenib Mesylate

Lumbar Puncture

Radiation Therapy

Trametinib Dimethyl Sulfoxide

A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)

The study consists of Safety Run-in and Phase 2 Cohorts.
The primary objectives of the safety run-in cohorts of this study are to evaluate the safety,
tolerability, and recommended Phase 2 dose (RP2D) of magrolimab in combination with
pembrolizumab + 5-fluorouracil (5-FU) + platinum chemotherapy, and docetaxel in combination
with magrolimab in participants with head and neck squamous cell carcinoma (HNSCC).
Phase 2 Cohorts 1: To evaluate the progression-free survival (PFS) with magrolimab in
combination with pembrolizumab + 5-FU + platinum versus pembrolizumab + 5-FU + platinum as
assessed by independent central review.
Phase 2 Cohorts 2 and 3: To evaluate the efficacy of magrolimab in combination with
pembrolizumab and magrolimab in combination with docetaxel as determined by the
investigator-assessed objective response rate (ORR).

Study of Magrolimab Combination Therapy in Participants With Head and Neck Squamous Cell Carcinoma

Sanford Roger Maris Cancer Center

Magrolimab

Pembrolizumab

Docetaxel

5-FU

Cisplatin

Carboplatin

Zimberelimab

A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

The purpose of this study is to characterize the distribution of lipoprotein(a) (Lp(a))
levels among participants with a history of ASCVD as defined by their medical history and is
2-fold:
-  Evaluate the distribution of Lp(a) value in the overall participants with documented
history of ASCVD
-  Evaluate the distribution of Lp(a) value in participants with documented history of
ASCVD by demographics and regions

A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)

Lillestol Research LLC

Lp(a) Screening

A Multicenter, Cross-sectional Study to Characterize the Distribution of Lipoprotein(a) Levels Among Patients With Documented History of Atherosclerotic Cardiovascular Disease

This phase III trial studies how well lenalidomide in combination with ixazomib works
compared to lenalidomide alone in treating patients with evidence of residual multiple
myeloma after stem cell transplantation. Lenalidomide may help shrink or slow the growth of
multiple myeloma. Ixazomib may stop the growth of cancer cells by blocking some of the
enzymes needed for cell growth. Giving lenalidomide and ixazomib together may work better
than giving lenalidomide alone in treating patients with evidence of residual multiple
myeloma after a stem cell transplantation.

Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

Ixazomib Citrate

Lenalidomide

Placebo Administration

Optimizing Prolonged Treatment in Myeloma Using MRD Assessment (OPTIMUM)

The purpose of this study is to evaluate the effect and safety of tirzepatide in participants
with obstructive sleep apnea and obesity who are both unwilling or unable to use Positive
Airway Pressure (PAP) therapy in GPI-1 and those who are and plan to stay on PAP therapy in
GPI-2.

Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

Lillestol Research

Tirzepatide

Placebo

A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial

The purpose of this study is to assess the contraceptive efficacy of relugolix combination
therapy.

Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy

Minot

Relugolix Combination Therapy

A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy

This study compares how three doses of semaglutide work in participants with type 2 diabetes
(T2D) and overweight who are taking metformin. The study will look mainly at how well
participant's blood sugar and participant's body weight are controlled when they are taking
the study medicine at different doses. Participants will either get semaglutide [2 milligrams
(mg), 8 mg, or 16 mg] or semaglutide placebo (a dummy medicine). Participants will take the
study medicine with an injection pen called NovoPen®4. The injection pen is a medical tool
with a needle used to inject the study medicine under the skin. The study will last for about
52 weeks. Participants will have 13 clinic visits and 4 phone calls.

A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight

Novo Nordisk Investigational Site

Semaglutide

Investigation of Once-weekly Semaglutide S.C. Dose-Response in Patients With Type 2 Diabetes and Overweight - a Participant- and Investigator-blinded and Sponsor Open-label Study

This phase II trial tests whether relugolix and radiation therapy works to shrink tumors in
patients with prostate cancer that has spread in a limited way to 1 to 5 other parts of the
body (oligometastatic). Testosterone can cause the growth of prostate cancer cells. Relugolix
lowers the amount of testosterone made by the body. This may help stop the growth of tumor
cells that need testosterone to grow. Giving relugolix with radiation therapy may help lower
the chance of prostate cancer growing or spreading.

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer

Relugolix

Stereotactic Body Radiation Therapy

A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)

This phase III trial compares the effect of adding whole brain radiotherapy with hippocampal
avoidance and memantine to stereotactic radiosurgery versus stereotactic radiosurgery alone
in treating patients with cancer that has spread to the brain and come back in other areas of
the brain after earlier stereotactic radiosurgery. Hippocampus avoidance during whole-brain
radiation therapy decreases the amount of radiation that is delivered to the hippocampus,
which is a brain structure that is important for memory. The medicine memantine is also often
given with whole brain radiation therapy because it may decrease the risk of side effects of
radiation on thinking and memory. Stereotactic radiosurgery delivers a high dose of radiation
only to the small areas of cancer in the brain and avoids the surrounding normal brain
tissue. Adding whole brain radiotherapy with hippocampal avoidance and memantine to
stereotactic radiosurgery may be effective in shrinking or stabilizing cancer that has spread
to the brain and returned in other areas of the brain after receiving stereotactic
radiosurgery.

Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

Memantine

Stereotactic Radiosurgery

Whole-Brain Radiotherapy

Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity &gt;/= 4 Brain Metastases/Year

North Dakota